// App-Quantinova.ai

POS0657 (2021) : GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

Researchers

Presenter

  • B. Combe

Principal Investigators

  • T. Matsubara

  • A. Pechonkina

  • Y. Tan

  • Z. Yin

  • J. Hong

  • R. Besuyen

  • A. Gomez-Centeno

  • M. H. Buch

Medical Centers

  • The University of Montpellier, Department of Rheumatology, CHU Montpellier, Montpellier, France

  • Matsubara Mayflower Hospital, Orthopaedic Surgery, Kato, Japan

  • Gilead Sciences, Inc., Biostatistics, Foster City, United States of America

  • Galapagos BV, Clinical Development, Leiden, Netherlands

  • Hospital Universitari Parc Taulí, Department of Rheumatology, Barcelona, Spain

  • School of Biological Sciences The University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom

Locations

  • France

  • Japan

  • United States

  • Netherlands

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Novartis

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved